Related Experiment Video

Updated: Mar 28, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

[Research Progress on Treating Acute Myeloid Leukemia by Midostaurin]

Yin-Ying Wang1, Wan-Ling Sun1

  • 1Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|December 29, 2015
PubMed

Insights

FLT3 gene mutations are common in acute myeloid leukemia (AML) and linked to poor prognosis. Midostaurin shows promise in treating FLT3-mutated AML by inhibiting FLT3 kinase activity and inducing apoptosis.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • FMS-like tyrosine kinase 3 (FLT3) gene mutations are found in ~30% of acute myeloid leukemia (AML) cases.
  • FLT3 mutations are associated with AML development and a poorer patient prognosis.
  • Targeting FLT3 mutations represents a potential therapeutic strategy for AML.

Purpose of the Study:

  • To review the association between FLT3 mutations and AML.
  • To summarize research advances and clinical applications of midostaurin in AML treatment.
  • To focus on midostaurin's efficacy in FLT3-mutated AML.

Main Methods:

  • Literature review of studies on FLT3 mutations in AML.
  • Analysis of midostaurin's mechanism of action.
  • Evaluation of clinical data regarding midostaurin's use in AML patients.

Main Results:

  • Midostaurin inhibits the FLT3 receptor tyrosine kinase.
  • Midostaurin induces cell cycle arrest and apoptosis in AML cells, including those with FLT3 mutations.
  • Midostaurin demonstrates clinical relevance in treating FLT3-mutated AML.

Conclusions:

  • FLT3 mutations are a significant factor in AML pathogenesis and prognosis.
  • Midostaurin is a viable therapeutic option for FLT3-mutated AML.
  • Further research into FLT3-targeted therapies is warranted for AML treatment.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

908
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K